Journal of Clinical and Aesthetic Dermatology

OCT 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/900562

Contents of this Issue

Navigation

Page 49 of 55

50 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY October 2017 • Volume 10 • Number 10 c ould still decide against a sale, according to the sources. A representative for the company declined to comment. * For more information, https://www.bloomberg.com/news/articles/201 7-11-01/novartis-is-said-to-weigh-sale-of- dermatology-generics-business NATIONAL ROSACEA SOCIETY ANNOUNCES GRANT RECIPIENTS FOR RESEARCH Three new studies will receive funding from the National Rosacea Society, according to a recent press release. The Society awarded $25,000 each to Benjamin Kaffenberger, MD; Raja Sivamani, MD, MS; and Hester Lim, MD. In addition, the Society announced it will continue to fund three existing grants for Anna Di Nardo, MD, PhD; Luis Garza, MD, PhD; and Wenqing Li, PhD. * For more information, https://www.rosacea.org/press/national- rosacea-society-awards-new-grants-medical- research-2 TANNING SALONS OFTEN IGNORE LAWS RESTRICTING USE BY MINORS Reuters recently reported on a study that revealed more than one-third of indoor tanning salons don't follow state laws limiting use by children and teens. Researchers posing as minors called 427 tanning salons in 42 states and the District of Columbia and said they wanted to tan before an upcoming family vacation. Tanning facility employees were asked about session costs and whether a parent needed to be present to consent to the tanning session. Overall, 159 salons, or 37 percent, failed to follow state laws restricting access for minors, the study found. * For more information, https://www.reuters.com/article/us-teens- tanning/tanning-salons-often-ignore-laws- restricting-use-by-minors-idUSKBN1D15FO NEW DERMATOLOGY DRUGS INTRODUCED IN 2017 An article in Pharmacy Times discussed new dermatology drugs approved by the FDA and introduced to the market in 2017. The drugs featured include Rhofade (oxymetazoline HCl cream, 1%), SILIQ (brodalumab), and Tremfya (guselkumab). * For more information, http://www.pharmacytimes.com/contributor/mari lyn-bulloch-pharmd-bcps/2017/10/new-drugs- introduced-in-2017-dermatology PROCEDURAL DERMATOLOGY POSITIONS INCREASED OVER RECENT 10-YEAR PERIOD According to recent findings, there has been a large increase in procedural dermatology positions in the past 10 years. However, this increase coincided with stagnation in dermatopathology. The reasons for the plateaued growth observed in dermatopathology positions are unclear, the researchers said. * For more information, visit https://www.healio.com/dermatology/practice- management/news/online/%7B79c9b922-512c- 42a4-9ec1-205030b3e61e%7D/procedural- dermatology-positions-increased-over-recent-10- year-period NEW JOURNAL, BIOMEDICAL DERMATOLOGY, LAUNCHES THIS MONTH The new journal, according to Managing Editor Jinhyuk Jung of Harvard Medical School, provides an opportunity to bring together expertise in the areas of stem cell/iPSC technology in dermatology, generating autologous artificial skin for research, and personalized cell therapy to achieve scientific improvement as well as further applications to industry by understanding dermatology through rigorous research. It is the official journal of the Korea Institute of Dermatological Sciences. * For more information, https://blogs.biomedcentral.com/on- m edicine/2017/10/17/introducing-biomedical- dermatology/ THE THERAPEUTIC LADDER APPROACH FOR ATOPIC DERMATITIS In an article published in the book series Advances in Experimental Medicine and Biology, Kalyani S. Marathe, MD, and William S. Farmer, BS, both of George Washington University in Washington, DC, describe a "therapeutic ladder" approach designed to help clinicians and patients select treatments appropriately. The first rung of the therapeutic ladder is treatment with topical glucocorticoids and topical calcineurin inhibitors. The second rung on the ladder includes more topical agents, including coal tar, menthol, capsaicin, and doxepin. Once topical options have been exhausted, the third rung includes systemic agents such as sedating or non-sedating antihistamines, oral glucocorticoids, or cyclosporine A. If those primary systemic agents fail, the fourth and final rung in the therapeutic ladder for pruritus in AD includes neuromodulating or immunomodulating agents, such as immunosuppressants, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and opioid receptor modulators. * For more information, http://dermatologytimes.modernmedicine.com/de rmatology-times/news/atopic-dermatitis-are-you- employing-therapeutic-ladder-approach PHYSICIAN EXTENDERS REDUCE WAIT TIMES FOR DERMATOLOGY APPOINTMENTS A study in JAMA Dermatology investigated the average appointment wait time to see a dermatologist in Ohio in order to determine the effects of the availability of a physician extender on scheduling. The offices without available physician extender appointments had a mean wait time of 60 days to see a dermatologist while offices with a physician extender had a mean wait time of 48 days to see a dermatologist. "As a multitiered N E W S & T R E N D S

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - OCT 2017